---
title: "CSPC Pharmaceutical Says Ropivacaine Long-Acting Injection Approved For Clinical Trials In China"
description: "CSPC Pharmaceutical Group Ltd :ROPIVACAINE LONG-ACTING INJECTION APPROVED FOR CLINICAL TRIALS IN CHINAAPPROVAL FROM NMPA"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276051287.md"
published_at: "2026-02-16T10:50:46.000Z"
---

# CSPC Pharmaceutical Says Ropivacaine Long-Acting Injection Approved For Clinical Trials In China

> CSPC Pharmaceutical Group Ltd :ROPIVACAINE LONG-ACTING INJECTION APPROVED FOR CLINICAL TRIALS IN CHINAAPPROVAL FROM NMPA

CSPC Pharmaceutical Group Ltd :

-   ROPIVACAINE LONG-ACTING INJECTION APPROVED FOR CLINICAL TRIALS IN CHINA
-   APPROVAL FROM NMPA

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)
- [562050.CN - Hwabao WP CSI Pharmaceuticals ETF](https://longbridge.com/en/quote/562050.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection | Shanghai Fosun Pharma says NMPA accepts drug registration application of moxetomidate hydrochloride injection | [Link](https://longbridge.com/en/news/275915279.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| Sun Pharmaceutical Industries Limited (SUNPHARMA) Gets a Buy from Geojit Research | In a report released today, from Geojit Research maintained a Buy rating on Sun Pharmaceutical Industries Limited, with  | [Link](https://longbridge.com/en/news/276165443.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.